Alnylam Pharmaceuticals, Inc. (ALNY) Reports Q3 Loss of 31c/Share
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts ALNY Hot Sheet
Price: $174.00 -25.13%
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Financial Fact:
Comprehensive loss: -109.41M
Today's EPS Names:
RBKB, ASBH, CMSG, More
Join SI Premium – FREE
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) reported Q3 EPS of ($0.31), $0.04 better than the analyst estimate of ($0.35). Revenue for the quarter came in at $20.8 million versus the consensus estimate of $20.51 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Downgrades Alnylam Pharmaceuticals (ALNY) to Hold
- SPS Commerce (SPSC) Tops Q3 EPS by 16c; Offers Guidance
- H.C. Wainwright Reiterates Buy Rating on Alnylam Pharmaceuticals (ALNY)
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
